Get started
Author

Katharina Seystahl

Observed names: K Seystahl, K. Seystahl, Seystahl, K, Seystahl, Katharina, Seystahl, Katharina Gertrud
Observed institutions: F. Hoffmann-La Roche AG, University of Helsinki, Inserm, University of Graz, University of Zurich, Université de Lille, University of Würzburg, Helsinki University Hospital, University Hospital of Bern, Erasmus MC, Centre Hospitalier Universitaire Vaudois, University Hospital of Basel, The Netherlands Cancer Institute, Centre Hospitalier Universitaire de Lille, LMU Klinikum, Roche Pharma AG (Germany), University Hospital Zurich, Comprehensive Cancer Center Mainfranken, BioTechMed-Graz, Luzerner Kantonsspital, Centre Oscar Lambret, Erasmus MC Cancer Institute, Medical University of Vienna, Ludwig-Maximilians-Universität München, Leipzig University, University of Lausanne
ORCID: 0000-0002-4072-5669
Observed ORCID: 0000-0002-4072-5669
OpenAlex ID: A5068539191
Therapeutic options in recurrent glioblastoma—An update
2016 · Katharina Seystahl, Wolfgang Wick, et al. · Critical Reviews in Oncology/Hematology · 211
PDF
Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE/-TOC uptake
2016 · Katharina Seystahl, Veit Stoecklein, et al. · Neuro-Oncology · 144
PDF
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors
2020 · Emilie Le Rhun, Patrick Devos, et al. · Neuro-Oncology · 136
PDF
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
2016 · Emese Szabo, Hannah Schneider, et al. · Neuro-Oncology · 84
PDF
Differential regulation of TGF-β–induced, ALK-5–mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma
2014 · Katharina Seystahl, Isabel Tritschler, et al. · Neuro-Oncology · 81
PDF
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
2015 · Julia Furtner, Veronika Schöpf, et al. · Neuro-Oncology · 71
PDF
Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
2017 · Katharina Seystahl, Alexandros Papachristodoulou, et al. · Molecular Cancer Therapeutics · 63
PDF
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol
2024 · Maximilian Mastall, Patrick Roth, et al. · BMC Cancer · 41
PDF
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression
2018 · Raymond Y Huang, Prashin Unadkat, et al. · Neuro-Oncology · 41
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
2012 · Nicole Hassold, Katharina Seystahl, et al. · International Journal of Cancer · 41
Limited role for transforming growth factor–β pathway activation-mediated escape from VEGF inhibition in murine glioma models
2016 · Davide Mangani, Michael Weller, et al. · Neuro-Oncology · 37
PDF
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older
2023 · Christina Stadler, Dorothee Gramatzki, et al. · Neuro-Oncology Practice · 31
PDF
Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives
2016 · Katharina Seystahl, Dorothee Gramatzki, et al. · Expert Opinion on Pharmacotherapy · 30
PDF
Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas
2012 · Katharina Seystahl, Benedikt Wiestler, et al. · European Neurology · 28
PDF
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
2012 · Katharina Seystahl, Michael Weller · Expert Opinion on Investigational Drugs · 28
PDF
Venous thromboembolic events in glioblastoma patients: An epidemiological study
2022 · Amanda Eisele, Katharina Seystahl, et al. · European Journal of Neurology · 26
PDF
Antiangiogenic Treatment for Multiple CNS Hemangioblastomas
2012 · Christian Riklin, Katharina Seystahl, et al. · Onkologie · 26
PDF
Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma
2019 · the German Glioma Network, Katharina Seystahl, et al. · Journal of Cancer Research and Clinical Oncology · 25
Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration
2021 · Martina Sebök, Christiaan Hendrik Bas van Niftrik, et al. · Neuro-Oncology Advances · 24
PDF
End-of-life care for glioma patients; the caregivers’ perspective
2020 · Caroline Hertler, Günter Eisele, et al. · Journal of Neuro-Oncology · 23
Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge
2021 · Vittorio Stumpo, Martina Sebök, et al. · Magnetic Resonance Materials in Physics Biology and Medicine · 20
PDF
Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab
2022 · Caroline Hertler, Katharina Seystahl, et al. · Neuro-Oncology · 16
PDF
Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome
2020 · Martina Sebök, Christiaan Hendrik Bas van Niftrik, et al. · The Cerebellum · 15
PDF
Neuropathological Characteristics of Progression after Prolonged Response to Bevacizumab in Multifocal Hemangioblastoma
2014 · Katharina Seystahl, Michael Weller, et al. · Oncology Research and Treatment · 15
PDF
Cancer is associated with inferior outcome in patients with ischemic stroke
2021 · Katharina Seystahl, Alessia Hug, et al. · Journal of Neurology · 14
PDF
Works count: 94
Citation count: 1,396
H-index: 20
I10-index: 32
Year
Topic
Type